The failure of Novartis's Lp(a) study was foreshadowed by its extended timeline. When events in an outcome-based trial occur slower than modeled, it suggests a mispowered study or misunderstood background factors, almost always leading to a negative result. Amgen's similar issue is a warning sign.

The failure of Novartis's antisense drug Pella Carson, contrasted with the potential success of Amgen's siRNA targeting the same pathway, could have a profound negative impact on the entire antisense field, favoring siRNA technology for large population diseases.

Recent failures in trials for hsCRP and Lp(a) targets highlight a growing challenge in cardiovascular R&D. Existing treatments like statins and GLP-1s have raised the standard of care so high that proving an incremental benefit for a new drug is incredibly difficult, requiring massive, expensive, and often unsuccessful studies.

Novartis's cardio drug failure in a secondary prevention trial highlights a critical development challenge: even for genetically-validated targets, intervening late in a chronic disease's progression may be ineffective. The damage may already be too extensive, suggesting earlier treatment is needed to show a benefit.

Novartis's Lp(a) drug may have failed not because the target is wrong, but because patients were already so well-treated with existing drugs like statins. This highlights a growing challenge: new therapies must demonstrate significant added value over an increasingly effective standard of care.

The surprising failures of Novartis's and Novo Nordisk's heart drugs, both targeting 'genetically validated' pathways, have debunked the widely held belief that genetic data guarantees clinical success. This forces a fundamental rethink of using genetics to de-risk massive drug development investments.

Two major cardiovascular trials targeting novel biomarkers (LPA and hs-CRP) failed to improve outcomes despite successfully lowering the biomarkers. This has dampened enthusiasm for novel targets and shifted R&D and investor focus back to established, "unsexy" pathways like PCSK9, GLP-1, and SGLT2, which are now viewed as less risky.

The Phase 3 failure of Novartis's cardiovascular drug Pella Carson triggered a massive sell-off not just for Novartis, but also for competitors Amgen and Eli Lilly. This indicates investor fear that the entire LP(a) drug target class is flawed, rather than it being an issue with a single company's molecule.

Novartis's LP(a) drug failed in patients with established cardiovascular disease, suggesting that the underlying vascular damage from a lifetime of exposure may be irreversible. This implies effective treatment might require intervention decades earlier, a timeline that poses significant, perhaps insurmountable, challenges for clinical trials and regulatory approval.